Filing Flows › Arrowhead Pharmaceuticals (ARWR) › R&D spending
Arrowhead Pharmaceuticals (ARWR) R&D spending by quarter
Arrowhead Pharmaceuticals' R&D spending was $198M in Q3 FY26 (third quarter fiscal 2026), +14% from Q2 FY26. Over the last 6 quarters it ranged from $133M (Q2 FY25) to $198M (Q3 FY26).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 FY26 | $198M | +14% | +22% |
| Q2 FY26 | $173M | -2% | +30% |
| Q1 FY26 | $177M | +1% | — |
| Q4 FY25 | $175M | +8% | — |
| Q3 FY25 | $162M | +22% | — |
| Q2 FY25 | $133M | — | — |
Q3 FY26 at a glance
Arrowhead Pharmaceuticals, Q3 FY26: revenue $75.3M (+171% year over year), operating margin -226.0%, net loss $179M, operating cash flow −$177M. The chart follows the revenue to costs, profit and cash.
Questions
What is Arrowhead Pharmaceuticals' R&D spending?
Arrowhead Pharmaceuticals' R&D spending was $198M in Q3 FY26 (third quarter fiscal 2026), +14% from Q2 FY26.
How has Arrowhead Pharmaceuticals' R&D spending changed?
Over the last 6 quarters it ranged from $133M (Q2 FY25) to $198M (Q3 FY26).
Q3 FY26 results → · How Arrowhead Pharmaceuticals makes money →